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ered to the bone marrow as compared with the liver. There was a
linear relationship between the infused dose of Y-90 and the
estimated radiation dose delivered to the BM. Mean absorbed
radiation doses were: bone marrow 10.23  1.8 cGy/MBq; liver
2.67  2.0 cGy/MBq; spleen 7.10  3.75 cGy/MBq. Total ab-
sorbed radiation doses at each Y-90 dose level are shown in Table
1. No additional toxicity due to the additional radiation was seen.
Engraftment: neutrophils 	0.5 by day 13.8 (range 11-22); plate-
lets 	50 by day 12.7 (range 10-22), no graft failures. In one
patient with myeloma, focal uptake of radiolabelled antibody was
seen at sites of disease activity suggesting in vivo targeting of
myeloma. This is consistent with our ﬁnding of CD66 antigen
expression by malignant plasma cells as shown by ﬂow cytometry.
There was a trend to greater disease response as the radiation dose
increased, with a greater proportion of patients at the higher
radiation dose levels achieving a CR. Conclusions: The radiola-
belled anti-CD66 monoclonal antibody showed consistently excel-
lent BM targeting and very low uptake by non-haematopoietic
organs. Up to 30 Gy of radiation was delivered to the BM with no
additional toxicity to other organs. Phase II studies are under way
using the Y-90-labelled anti-CD66 in RIC-allogeneic SCT proto-
cols and for autologous SCT for myeloma.
Table 1. Organ Dosimetry
Dose level
(MBqkg)
Organ Dose in (Gy)
Bone Marrow Liver Spleen
5 4.1 1.4 1.1
10 9.1 1.3 2.4
25 15.6 3.7 12.6
37.5 25.0 7.4 5.1
GVH/GVL
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PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE DESPITE COM-
PENSATORY FUNCTION OF LYMPHOID ORGANS IN VIVO
Beilhack, A.1, Schulz, S.1,2, Baker, J.1, Beilhack, G.F.1,
Nishimura, R.1, Landan, G.1, Baker, E.M.1, Herman, E.I.1,
Butcher, E.C.3, Contag, C.H.4, Negrin, R.S.1 1Division of Blood &
Marrow Transplantation, Stanford University, Stanford, CA; 2Institute
of Pathology, Technical University Munich, Germany; 3Department of
Pathology, Stanford University, Stanford, CA; 4Department of Pediat-
rics, Stanford University, Stanford, CA.
Acute graft-versus-host disease (aGVHD) results from allo-
reactive donor derived T cells attacking targets in the gastroin-
testinal tract, liver and skin. We observed the initiation and
rapid kinetics of aGVHD in a murine model [FVB/N (H-2q)
into irradiated BALB/c (H-2d)] using in vivo bioluminescence
imaging. The transition from the initiation to the effector phase
of aGVHD (day 3-4) was characterized by rapid T cell prolif-
eration and upregulation of gut homing receptors 
47, 
E7
and CCR9 on alloreactive T cells in Peyer’s patches (PP),
mesenteric lymph nodes (LN) and spleen, but not peripheral
LNs. Therefore we asked whether the lack of speciﬁc lymphoid
priming sites would lead to decreased alloreactive T cell inﬁl-
tration in the gut compared to the liver and skin. Using PP
deﬁcient mice, we observed that mesenteric LN and spleen
compensate for the lack of PP as alloreactive priming sites.
Transplantation of PP and LN deﬁcient mice (LT
/) showed
that the spleen alone was sufﬁcient to cause the complete proﬁle
of aGVHD with a time course similar to that of wild-type mice.
Splenectomized mice with intact secondary lymphoid organs
also developed aGVHD. Strikingly, treatment of splenecto-
mized recipients with blocking antibodies against the lymphoid
homing receptors l-selectin and MAdCAM-1 prevented GVHD
with 100% survival (	120 d, P  .0001). Our study shows that
multiple priming sites are involved in GVHD initiation, the
spleen compensating for the lack of PP and mesenteric LN, and
vice versa. In contrast, splenectomy and antibody blocking re-
sulted in a clear survival beneﬁt for all recipients. A.B. and S.S.
contributed equally to this study.
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THE HAPLOIMMUNOSTORM SYNDROME: A DISTINCT CLINICAL ENTITY
SEEN IN HLA-HAPLOIDENTICAL CELLULAR IMMUNOTHERAPY
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An immune-mediated anti-tumor response is the ultimate goal of
allogeneic transplantation for relapsed, refractory malignancies.
We developed a transplant protocol with less toxicity compared
with standard allogeneic transplantation. We utilized multiple do-
nor lymphocyte infusions after nonmyeloablative HLA-haploiden-
tical stem cell transplantation for refractory disease. We have
performed a total of 41 HLA-mismatched transplants with escala-
tion of the CD3 dose to 2  108 cells/kg using G-CSF primed
product, with a conditioning regimen of 100 cGy total body irra-
diation. Our phase I/II study had 26 with hematologic malignan-
cies. This therapy results in loss of detectable macrochimerism.
Despite this, 13 responses, six major, occurred outside of macro-
chimerism. We have observed a new infusion related clinical entity
named haploimmunostorm (HIS), observed after infusion. This
syndrome occurred in 26 out of 30 (87%) patients with a CD3
dose more than 1  108 cells/kg. In the syndrome, a constellation
of symptoms occurred, some with variable penetrance, in which
hyperpyrexia and malaise were a constant feature occurring as early
as 4 hrs after cell infusion (median of 14 hrs). A morbilliform rash
was seen in 40% of patients. Biopsies revealed no evidence of
hyperacute or acute GVHD. Diarrhea was present in a 20% of
patients; biopsies taken also failed to show any evidence of GVHD.
Transient elevations of liver enzymes occurred in 40% of the
patients usually. Steroids were used successfully if the HIS syn-
drome lasted more than 72 hrs. We used a Bioplex machine and
analyzed 17 separate cytokine levels serially in these patients be-
ginning with pre-treatment levels. Cytokine level analysis showed
up to a 90 fold increase in baseline cytokine levels with signiﬁcant
increases of at least 10 fold in IFN-, IL-10, IL-13, IL-2, IL-5,
IL-6, IL-7, IL-8, MCP-1, and MIP-1. This syndrome appears to
be immunologically based and represents neither hyperacute nor
acute GVHD. This syndrome is different than an engraftment
syndrome reported in some patients undergoing autologous trans-
plant. Engraftment syndrome occurs at time of engraftment, op-
posed to HIS in which may be a rejection syndrome. Engraftment
syndrome is similar to HIS but deviates with presence of capillary
leak and pulmonary inﬁltrates. In summary, we have observed a
new clinical entity that was not previously seen and is a result of the
donors having a relatively intact immune system at the time of cell
infusion.
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STATISTICAL MODELLING FOR CLINICAL AND GENETIC RISK FACTORS
FOR GvHD AND SURVIVAL IN A COHORT OF EUROPEAN HLA MATCHED
SIBLING TRANSPLANTS
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A cohort of 244 HLA matched sibling transplants from 5
centres within Europe were typed for SNPs or microsatellites
(IL-1R
, IL-4, IL-6, IL-10, IFN, TNF
, TNFR11, and ste-
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